Christopher Gene Kevil

US Patent:

20110311653, Dec 22, 2011

Filed:

Nov 17, 2008

Appl. No.:

12/741436

Inventors:

Christopher Kevil - Shreveport LA, US
David Lefer - Decatur GA, US
Rakesh Patel - Hoover AL, US

Assignee:

THE UAB RESEARCH FOUNDATION - Birmingham AL
LOUISIANA STATE UNIVERSITY - Baton Rouge LA

International Classification:

A61K 33/06
A61P 3/10
A61P 19/00
A61K 33/00
A61P 9/10

US Classification:

424696, 424718

Abstract:

Methods of treating a subject who has chronic tissue ischemia are disclosed. The methods can include administering to the subject a pharmaceutical composition comprising inorganic nitrite or a pharmaceutically acceptable salt thereof, for a time and in an amount sufficient to result in blood vessel growth in the ischemic tissue. The subject can be diagnosed as having a medical condition that results in persistent or recurring restriction of blood supply to a tissue, for example, peripheral artery disease, diabetes, atherosclerotic cardiovascular disease or defective wound healing. The methods can include the step of identifying a suitable subject.

US Patent:

20120237617, Sep 20, 2012

Filed:

May 26, 2010

Appl. No.:

13/378530

Inventors:

Christopher Kevil - Shreveport LA, US

Assignee:

TheraVasc Inc. - Cleveland OH

International Classification:

A61K 33/00
A61P 29/00
A61P 43/00
A61P 17/00
A61P 9/00
A61P 3/10
A61P 9/10
A61P 1/00
A61P 19/08
A61P 25/02
A61P 31/00
A61P 19/02
A61P 31/04
A61P 31/10
A61K 33/06

US Classification:

424682, 424718

Abstract:

Methods of treating a subject who has an tissue damage or who is at risk for tissue necrosis are disclosed. Also disclosed are methods of treating a subject who has an inflammatory disorder. The methods can include administering to the subject a pharmaceutical composition comprising inorganic nitrite or a pharmaceutically acceptable salt thereof, for a time and in an amount sufficient to reduce the tissue damage. The subject can be diagnosed as having a medical condition that results tissue damage, for example, diabetes, peripheral artery disease, cardiovascular disease, defective wound healing, arthritis, inflammatory bowel disease, ischemia, or a bacterial infection, e.g., Group A staphylococcal infection. The methods can include the step of monitoring the course of treatment.

US Patent:

20140073565, Mar 13, 2014

Filed:

Sep 12, 2013

Appl. No.:

14/024751

Inventors:

Christopher Kevil - Shreveport LA, US
Robert McVie - Shreveport LA, US
John Glawe - Benton LA, US

Assignee:

Board of Supervisors of Louisiana State University and Agricultural and Mechanical College - Baton Rouge LA

International Classification:

G01N 33/50

US Classification:

514 69

Abstract:

CXCR4 and ROBO-1 are biomarkers associated with type 1 diabetes. Expression of CXCR4 and ROBO-1 in peripheral CD3 T cells is substantially higher in patients with autoimmune diabetes (type 1 diabetes) than in non-diabetic patients. Therapies are disclosed for reducing the progression of type 1 diabetes, and to reduce the risk of developing type 1 diabetes in patients who are at risk of developing type 1 diabetes.

US Patent:

20110086069, Apr 14, 2011

Filed:

Oct 14, 2010

Appl. No.:

12/904791

Inventors:

Christopher KEVIL - Shreveport LA, US
Anthony GIORDANO - Shreveport LA, US
Douglas R. FLANAGAN - Iowa City IA, US
Panayiotis P. CONSTANTINIDES - Gurnee IL, US

Assignee:

TheraVasc, LLC - Cleveland OH

International Classification:

A61K 33/00
A61K 9/00
A61P 9/10
A61P 7/00

US Classification:

424400, 424718

Abstract:

The present invention relates to pharmaceutical compositions of nitrites such as inorganic nitrites, or any pharmaceutically acceptable salts, solvates, or prodrugs thereof, and the medical use of these compositions. The pharmaceutical compositions, which can be formulated for oral administration, can provide immediate release or extended release of the nitrite ion (NO). The pharmaceutical compositions of the invention are useful, for example, for the treatment of chronic tissue ischemia.

US Patent:

20220409637, Dec 29, 2022

Filed:

Sep 6, 2022

Appl. No.:

17/903138

Inventors:

- Baton Rouge LA, US
Christopher KEVIL - Shreveport LA, US
Mansoureh BARZEGAR - Lafayette LA, US
Ana Maria DRAGOI - Shreveport LA, US

Assignee:

Board of Supervisors of Louisiana State University and Agricultural and Mechanical College - Baton Rouge LA

International Classification:

A61K 31/655
A61K 31/397

Abstract:

Therapeutics and methods of treating COVID-19 in a patient in need thereof comprising administering a pharmaceutically effective dose of a therapeutic, wherein the therapeutic contains an ACE2 externalizer, and the ACE2 externalizer is one of diminazene, diminazene aceturate, or a pharmaceutically acceptable salt, solvate, ester, amide, clathrate, stereoisomer, enantiomer, or prodrug thereof.

US Patent:

20220273702, Sep 1, 2022

Filed:

Feb 25, 2022

Appl. No.:

17/681705

Inventors:

- Baton Rouge LA, US
Christopher KEVIL - Shreveport LA, US
Paari DOMINIC - Shreveport LA, US
Anthony Wayne ORR - Benton LA, US

Assignee:

Board of Supervisors of Louisiana State University and Agricultural and Mechanical College - Baton Rouge LA

International Classification:

A61K 33/04
A61K 33/00
A61K 31/715
G01N 33/84

Abstract:

Therapeutics and methods of treating COVID-19 comprising in a patient comprising administering to the patient an effective dose of a pharmacologic composition containing a first therapeutic; wherein the first therapeutic is a hydrogen sulfide (H2S) donor, or a salt, solvate, ester, amide, clathrate, stereoisomer, enantiomer, prodrug or analogs thereof. According to a further embodiment the H2S donor is one of include diallyl trisulfide (DATS), diallyl disulfide (DADS), sodium sulfide, acillin, sugammadex, sulfanilamide, disulfram, sulfonamide, a sulfinate, a sulfoxide, a persulfide, a polysulfide, and a sulfone. According to a further embodiment the pharmacologic composition further contains a second therapeutic, wherein the second therapeutic is a nitrite, or a salt, solvate, ester, amide, clathrate, stereoisomer, enantiomer, prodrug or analogs thereof. According to a further embodiment wherein the nitrite is an inorganic nitrite.

US Patent:

20210379016, Dec 9, 2021

Filed:

Jun 7, 2021

Appl. No.:

17/341249

Inventors:

- Baton Rouge LA, US
Christopher KEVIL - Shreveport LA, US
Anthony Wayne ORR - Benton LA, US
Chowdhury S ABDULLAH - Shreveport LA, US
Richa Aishwarya - Shreveport LA, US

Assignee:

Board of Supervisors of Louisiana State University and Agricultural and Mechanical College - Baton Rouge LA

International Classification:

A61K 31/4015
A61K 45/06
A61K 31/55
A61K 31/5375
A61K 31/341
A61K 31/445
A61K 31/57

Abstract:

Therapeutics and methods of treating one of an angiotensin-converting enzyme 2 (ACE2) associated condition and an ACE2 associated pre-condition patient comprising administering to the patient a pharmaceutically therapeutic dose of a therapeutic, wherein the therapeutic includes either a Sigmar1 antagonist or any pharmaceutically acceptable salt, solvate, or prodrug thereof, or a Sigmar1 enhancer, or any pharmaceutically acceptable salt, solvate, or prodrug thereof. A method of treating coronavirus disease 2019 (COVID-19) patient comprising administering to the patient a pharmaceutically therapeutic dose of a therapeutic, wherein the therapeutic includes a Sigmar1 enhancer, or any pharmaceutically acceptable salt, solvate, or prodrug thereof.

US Patent:

20210346409, Nov 11, 2021

Filed:

May 7, 2021

Appl. No.:

17/315249

Inventors:

- Baton Rouge LA, US
Christopher KEVIL - Shreveport LA, US
Mansoureh BARZEGAR - Lafayette LA, US
Ana Maria DRAGOI - Shreveport LA, US

Assignee:

Board of Supervisors of Louisiana State University and Agricultural and Mechanical College - Baton Rouge LA

International Classification:

A61K 31/655
A61K 31/397
A61K 31/4184
A61K 31/41
A61K 31/366
A61K 31/22
A61K 31/405
A61K 31/505
A61K 31/4418
A61K 31/40
A61K 31/47
A61K 31/4245
A61K 31/4178

Abstract:

Therapeutics and methods of treating COVID-19 in a patient in need thereof comprising administering a pharmaceutical composition containing a pharmaceutically effective dose of a therapeutic, wherein the therapeutic contains both an ACE2 externalizer and one or more ACE2 internalization preventors. Methods of treatment and pharmaceutical compositions comprising an ACE2 externalizer and one or more ACE2 internalization preventors.